Skip to main content

Monoclonal Antibody Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$480M
Range: $255M - $695M
Total Deal Value
$2.5B
Range: $1.6B - $3.5B
Royalty Rate
13.2% - 22.1%
Tiered up to 26.1%
Dev Milestones
$405M
Range: $259M - $552M
Model Your Deal

Market Analysis

Monoclonal Antibody therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in immunology & autoimmune is $480M, with total deal values reaching $2.5B. Development milestones average $405M, while regulatory milestones contribute $708M.

The immunology & autoimmune monoclonal antibody landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody immunology & autoimmune deals range from 13.2% to 22.1% at the base tier, with tiered escalation reaching 17.2%-26.1% on blockbuster sales. Commercial milestones averaging $911M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 monoclonal antibody licensing deals in immunology & autoimmune average $480M in upfront payments, with a range of $255M to $695M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for monoclonal antibody immunology & autoimmune transactions?
The median total deal value for Phase 2 monoclonal antibody assets in immunology & autoimmune is $2.5B, ranging from $1.6B to $3.5B. This includes development milestones ($405M), regulatory milestones ($708M), and commercial milestones ($911M).
What royalty rates are standard for monoclonal antibody deals in immunology & autoimmune?
Base royalty rates for monoclonal antibody immunology & autoimmune transactions range from 13.2% to 22.1%, with tiered escalations reaching 17.2%-26.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in monoclonal antibody immunology & autoimmune deals?
Monoclonal Antibody immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($405M) make up the largest share, followed by commercial milestones ($911M) and regulatory milestones ($708M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Bispecific Antibody in Immunology & Autoimmune

View

Monoclonal Antibody in Oncology

View

Monoclonal Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included